Linagliptin STADA

What Is Linagliptin STADA and What Is It Used For?

Quick Answer: Linagliptin STADA is a DPP-4 inhibitor (gliptin) used to lower blood sugar in adults with type 2 diabetes mellitus. It works by preventing the breakdown of incretin hormones, which stimulate insulin release and suppress glucagon in response to meals. It is taken once daily as a 5 mg film-coated tablet.

Linagliptin belongs to the pharmacological class of dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly referred to as gliptins. This class of oral antidiabetic agents was developed to exploit the physiological incretin system — a hormonal pathway that plays a central role in glucose homeostasis after meals. When you eat, the gut releases incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones stimulate the pancreas to release insulin and suppress the release of glucagon, both in a glucose-dependent manner. Under normal conditions, incretins are rapidly degraded by the enzyme DPP-4 within minutes of release.

By selectively and reversibly inhibiting DPP-4, linagliptin extends the half-life and increases the circulating levels of active GLP-1 and GIP. This results in enhanced insulin secretion and reduced glucagon output specifically when blood glucose is elevated — a mechanism that inherently carries a low risk of hypoglycemia. The glucose-dependent nature of this action is a key pharmacological advantage: when blood sugar levels are normal or low, the incretin effect is diminished, providing an inbuilt safety mechanism against excessive insulin release.

Linagliptin STADA is a generic formulation of linagliptin, containing the same 5 mg dose of the active substance as the original branded product. It is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycemic control in several clinical scenarios. It may be used as monotherapy when metformin is inappropriate due to intolerance or contraindication (particularly in patients with moderate to severe renal impairment). More commonly, linagliptin is prescribed as add-on combination therapy alongside metformin, a sulfonylurea plus metformin, pioglitazone, or insulin (with or without metformin), when these agents alone do not provide adequate blood sugar control.

The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) position DPP-4 inhibitors as a reasonable second-line or third-line option in the management of type 2 diabetes, particularly when there is a need for a weight-neutral medication with a low risk of hypoglycemia. The 2022 ADA/EASD Consensus Report on Management of Hyperglycemia in Type 2 Diabetes recommends that the choice of glucose-lowering therapy should be guided by patient-centered factors including comorbidities, risk of adverse effects, cost, and patient preference.

A distinguishing pharmacokinetic feature of linagliptin is its predominantly non-renal elimination. Unlike most other DPP-4 inhibitors (such as sitagliptin, saxagliptin, or alogliptin), which are primarily cleared by the kidneys and require dose adjustments in renal impairment, linagliptin is primarily excreted unchanged via the bile and gut. Less than 5% of the absorbed dose is eliminated by the kidneys. This unique pharmacokinetic profile means that no dose adjustment is required in patients with any degree of renal impairment, including end-stage renal disease and dialysis — making linagliptin a particularly attractive option for the large proportion of type 2 diabetes patients who have concurrent chronic kidney disease.

What Should You Know Before Taking Linagliptin STADA?

Quick Answer: Do not take linagliptin if you are allergic to it. It is not suitable for type 1 diabetes or diabetic ketoacidosis. Inform your doctor if you have a history of pancreatitis, heart failure, or if you are taking sulfonylureas or insulin, as dose adjustments of those medications may be needed.

Contraindications

The primary contraindication for linagliptin is known hypersensitivity to the active substance or to any of the excipients in the formulation. Hypersensitivity reactions reported with DPP-4 inhibitors have included anaphylaxis, angioedema, and exfoliative skin conditions. If you have experienced any such reaction to linagliptin or another DPP-4 inhibitor in the past, you must not take this medicine.

Linagliptin is specifically indicated for type 2 diabetes mellitus and must not be used to treat type 1 diabetes or diabetic ketoacidosis (DKA). Type 1 diabetes is caused by autoimmune destruction of pancreatic beta cells and requires insulin replacement therapy. DPP-4 inhibitors depend on functioning beta cells to exert their glucose-lowering effect and are ineffective and potentially harmful in these conditions.

Warnings and Precautions

Several important clinical considerations should be discussed with your healthcare provider before starting linagliptin:

• Pancreatitis: Acute pancreatitis has been reported in patients taking DPP-4 inhibitors, including linagliptin. Patients should be informed about the characteristic symptoms of acute pancreatitis: persistent, severe abdominal pain that may radiate to the back, often accompanied by nausea and vomiting. If pancreatitis is suspected, linagliptin should be discontinued immediately. If acute pancreatitis is confirmed, treatment should not be restarted. Caution is advised in patients with a history of pancreatitis, although a causal relationship has not been definitively established.
• Hypoglycemia with sulfonylureas or insulin: When linagliptin is used in combination with a sulfonylurea (such as glimepiride or glibenclamide) or insulin, the risk of hypoglycemia is increased. Your doctor may consider reducing the dose of the sulfonylurea or insulin when adding linagliptin to minimize this risk. Patients should be educated about recognizing and managing hypoglycemic episodes.
• Heart failure: The CARMELINA trial evaluated cardiovascular outcomes in patients with type 2 diabetes at high cardiovascular and renal risk and did not show an increased risk of hospitalization for heart failure with linagliptin compared with placebo. However, clinical experience with DPP-4 inhibitors in patients with New York Heart Association (NYHA) functional class III–IV heart failure is limited. Linagliptin should be used with caution in these patients.
• Bullous pemphigoid: Cases of bullous pemphigoid (a blistering skin disease) have been reported with DPP-4 inhibitors. If bullous pemphigoid is suspected, linagliptin should be discontinued and dermatological referral considered.
• Immunocompromised patients: There is limited clinical experience with linagliptin in immunocompromised patients, including those who have undergone organ transplantation or have been diagnosed with human immunodeficiency virus (HIV). Linagliptin has not been specifically studied in these populations.

Pregnancy and Breastfeeding

There are no adequate clinical data from the use of linagliptin in pregnant women. Animal reproductive toxicity studies have not indicated direct harmful effects on fertility, pregnancy, embryonic development, or postnatal development. However, as a precautionary measure, the use of linagliptin during pregnancy is not recommended. Women who are pregnant, planning to become pregnant, or who discover they are pregnant while taking linagliptin should consult their healthcare provider for alternative diabetes management strategies, which typically involve insulin therapy.

It is not known whether linagliptin is excreted in human breast milk. Animal studies have shown excretion of linagliptin in milk. A risk to the breastfed infant cannot be excluded. Therefore, a decision should be made whether to discontinue breastfeeding or to discontinue linagliptin therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Always consult your healthcare provider before making changes to your diabetes treatment during breastfeeding.

Driving and Operating Machinery

Linagliptin has no or negligible influence on the ability to drive and use machines. However, patients should be alerted to the risk of hypoglycemia when linagliptin is used in combination with a sulfonylurea or insulin. Symptoms of hypoglycemia — including dizziness, tremor, sweating, confusion, and blurred vision — can impair the ability to drive or operate machinery safely. If you experience hypoglycemia, do not drive or use machines until symptoms have fully resolved.

How Does Linagliptin STADA Interact with Other Drugs?

Quick Answer: Linagliptin has a low potential for drug interactions. The most clinically relevant interaction is with rifampicin, a strong enzyme inducer that may reduce linagliptin's effectiveness. When combined with sulfonylureas or insulin, the dose of those agents may need to be reduced to prevent hypoglycemia.

Linagliptin has a relatively favorable drug interaction profile compared with many other antidiabetic agents. It is a substrate of the P-glycoprotein (P-gp) efflux transporter and cytochrome P450 enzyme CYP3A4, but it is a weak competitive inhibitor of CYP3A4 and does not inhibit or induce other CYP enzymes at clinically relevant concentrations. This means linagliptin is unlikely to cause pharmacokinetic interactions with medications metabolized by these pathways.

Clinical pharmacokinetic interaction studies have been conducted with a range of commonly co-prescribed medications, and no clinically meaningful interactions have been observed with metformin, glyburide (glibenclamide), pioglitazone, warfarin, digoxin, or oral contraceptives. Nevertheless, certain interactions warrant attention.

Clinically Significant Interactions

Additional Considerations

The interaction with rifampicin is the most clinically important. Rifampicin is a potent inducer of both CYP3A4 and P-glycoprotein. In a dedicated pharmacokinetic study, co-administration of multiple doses of rifampicin with linagliptin reduced the steady-state area under the curve (AUC) of linagliptin by approximately 40% and peak plasma concentration (Cmax) by approximately 44%. Because linagliptin achieves sustained DPP-4 inhibition at its approved 5 mg dose with some pharmacological margin, a 40% reduction in exposure may compromise its glucose-lowering efficacy. Therefore, the concurrent use of linagliptin with rifampicin (or other strong P-gp/CYP3A4 inducers such as carbamazepine, phenobarbital, or phenytoin) is not recommended. In patients requiring such agents, an alternative antidiabetic approach should be considered.

Conversely, strong CYP3A4/P-gp inhibitors such as ritonavir increase linagliptin exposure. However, clinical data suggest that the resulting increase in linagliptin levels does not reach a magnitude that would necessitate dose adjustment or cause safety concerns. This is because linagliptin has a wide therapeutic index, and higher plasma concentrations do not proportionally increase pharmacodynamic effects (DPP-4 inhibition is already near-maximal at the 5 mg dose).

No clinically relevant interactions have been demonstrated with warfarin (no effect on INR), digoxin (no effect on digoxin pharmacokinetics), or oral contraceptives (no effect on ethinylestradiol or levonorgestrel levels). Linagliptin can be safely combined with metformin, pioglitazone, and most commonly prescribed cardiovascular medications without dose adjustments.

What Is the Correct Dosage of Linagliptin STADA?

Quick Answer: The recommended dose is one 5 mg film-coated tablet taken once daily, at any time of day, with or without food. No dose adjustment is needed for renal or hepatic impairment. The tablet should be swallowed whole with water.

Linagliptin has the practical advantage of a simple, fixed-dose regimen that does not require titration or adjustment based on renal or hepatic function. This straightforward dosing simplifies treatment for both patients and healthcare providers, particularly in the elderly population and those with multiple comorbidities.

Adults

Children and Adolescents

Linagliptin is not recommended for use in children and adolescents below 18 years of age. The safety and efficacy of linagliptin have not been established in the pediatric population. Type 2 diabetes in children and adolescents is managed primarily with lifestyle interventions and metformin, with insulin as the mainstay pharmacological therapy. If your child has been diagnosed with type 2 diabetes, consult a pediatric endocrinologist for age-appropriate treatment guidance.

Elderly Patients

No dose adjustment is required for elderly patients based on age alone. Clinical trials have included a substantial proportion of patients aged 65 years and older, and the safety and efficacy profile was consistent with that observed in younger adults. However, elderly patients are more likely to have reduced renal function, multiple comorbidities, and polypharmacy, all of which increase the complexity of diabetes management. The fact that linagliptin does not require renal dose adjustment is particularly advantageous in this population. Elderly patients on combination therapy with sulfonylureas or insulin should be closely monitored for hypoglycemia.

Missed Dose

If you forget to take a dose, take it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and take your next dose at the usual time. Do not take a double dose on the same day to make up for a forgotten tablet. If you are unsure, consult your pharmacist or healthcare provider. Setting a daily alarm or linking your medication to an existing routine (such as breakfast or brushing your teeth) can help prevent missed doses.

Overdose

What Are the Side Effects of Linagliptin STADA?

Quick Answer: Linagliptin is generally well tolerated. The most commonly reported side effect is nasopharyngitis (common cold). Uncommon side effects include pancreatitis, hypersensitivity reactions, and cough. Hypoglycemia risk is increased when combined with sulfonylureas or insulin.

Like all medicines, linagliptin can cause side effects, although not everybody gets them. Overall, the safety profile of linagliptin has been well characterized across numerous clinical trials involving more than 10,000 patients with type 2 diabetes, including the large-scale cardiovascular outcomes trials CARMELINA (over 6,900 patients) and CAROLINA (over 6,000 patients). The incidence of adverse events with linagliptin was generally comparable to placebo, reflecting its favorable tolerability.

Nasopharyngitis is the most frequently reported adverse event in clinical trials, occurring at a slightly higher rate with linagliptin compared with placebo. The symptoms are generally mild and self-limiting, comprising typical cold-like symptoms such as nasal congestion, sore throat, and mild cough.

Hypoglycemia deserves special attention in the context of combination therapy. When linagliptin is used as monotherapy or in combination with metformin, the incidence of hypoglycemia is comparable to placebo and typically very low. However, when added to a sulfonylurea-based regimen or to insulin, the risk of hypoglycemia increases substantially because both sulfonylureas and insulin stimulate insulin secretion through glucose-independent mechanisms. In such combinations, the CAROLINA trial showed that the overall incidence of hypoglycemia with linagliptin plus standard care was significantly lower than with glimepiride plus standard care, highlighting the relatively lower intrinsic hypoglycemia risk of linagliptin within the context of second-line therapies.

Pancreatitis remains a topic of pharmacovigilance for all DPP-4 inhibitors. Although post-marketing reports exist, large-scale randomized trials (CARMELINA, CAROLINA) did not demonstrate a statistically significant increase in pancreatitis risk with linagliptin. Nevertheless, the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) continue to recommend that patients and prescribers remain vigilant. If pancreatitis is confirmed, linagliptin should be permanently discontinued.

Bullous pemphigoid is a rare but recognized class effect of DPP-4 inhibitors. This autoimmune blistering disease typically presents with large, tense blisters on the skin, often preceded by an itchy, eczematous eruption. Cases have been reported with all marketed DPP-4 inhibitors, and the condition usually resolves upon discontinuation of the drug, sometimes requiring additional immunosuppressive treatment.

Reporting Side Effects

If you experience any side effects, including any not listed above, talk to your doctor or pharmacist. You can also report suspected adverse reactions to your national pharmacovigilance authority (for example, the MHRA Yellow Card scheme in the United Kingdom, MedWatch in the United States, or EudraVigilance in the European Union). Reporting helps provide more information on the safety profile of this medicine and benefits all patients.

How Should You Store Linagliptin STADA?

Quick Answer: Store below 30°C (86°F) in the original packaging to protect from moisture. Keep out of the sight and reach of children. Do not use after the expiry date.

Proper storage of linagliptin tablets helps maintain the medication's stability, potency, and safety throughout its shelf life. Film-coated tablets are generally more stable than effervescent formulations, but they can still be affected by environmental conditions.

• Temperature: Store at or below 30°C (86°F). Do not refrigerate or freeze the tablets.
• Moisture protection: Keep the tablets in the original blister packaging until ready to take. The blister pack is designed to protect the tablets from moisture and light degradation.
• Light: No special light precautions are required, but storing in the original packaging provides additional protection.

Keep this medicine out of the sight and reach of children. Do not use linagliptin after the expiry date printed on the blister and carton (marked as “EXP”). The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment.

What Does Linagliptin STADA Contain?

Quick Answer: Each film-coated tablet contains 5 mg of the active ingredient linagliptin. The tablet also contains inactive ingredients (excipients) including mannitol, pregelatinized starch, maize starch, copovidone, and magnesium stearate, with a film coating of hypromellose, titanium dioxide, talc, macrogol, and iron oxide red.

Understanding the complete composition of your medication is important, particularly if you have known allergies or intolerances to specific ingredients. Each linagliptin film-coated tablet contains the following components:

Active Substance

The active pharmaceutical ingredient is linagliptin, present in a dose of 5 mg per tablet. Linagliptin (chemical name: 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione) is a xanthine-based DPP-4 inhibitor with high selectivity for the DPP-4 enzyme over related enzymes (DPP-8, DPP-9, and fibroblast activation protein alpha).

Inactive Ingredients (Excipients)

The excipients in the tablet core and film coating serve pharmaceutical functions including binding, disintegration, lubrication, and appearance:

Tablet core:

• Mannitol — filler and diluent
• Pregelatinized starch — binder and disintegrant
• Maize starch — disintegrant
• Copovidone — binder
• Magnesium stearate — lubricant (prevents tablet sticking during manufacturing)

Film coating:

• Hypromellose — film-forming agent
• Titanium dioxide (E171) — opacifier and white colorant
• Talc — glidant
• Macrogol (polyethylene glycol) — plasticizer
• Iron oxide red (E172) — colorant (gives the tablet its light pink appearance)

Tablet Appearance

Linagliptin STADA 5 mg tablets are light pink, round, biconvex film-coated tablets. The tablets may be debossed with identifying markings depending on the manufacturer. They are supplied in blister packs typically containing 28, 30, 56, 60, 84, 90, 98, or 100 tablets per carton, although not all pack sizes may be marketed in every country.